WWW.DISSERTATION.XLIBX.INFO
FREE ELECTRONIC LIBRARY - Dissertations, online materials
 
<< HOME
CONTACTS



Pages:   || 2 | 3 | 4 | 5 |   ...   | 38 |

«Synthesis and structure-activity relationship of liposomal substrates for phospholipase A(2) Viart, Helene Marie-France; Clausen, Mads Hartvig ...»

-- [ Page 1 ] --

Downloaded from orbit.dtu.dk on: Nov 15, 2016

Synthesis and structure-activity relationship of liposomal substrates for

phospholipase A(2)

Viart, Helene Marie-France; Clausen, Mads Hartvig

Published in:

ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY

Publication date:

2011

Document Version

Publisher's PDF, also known as Version of record

Link to publication

Citation (APA):

Viart, H. M-F., & Clausen, M. H. (2011). Synthesis and structure-activity relationship of liposomal substrates for phospholipase A(2). ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 242, MEDI 344.

General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.

• You may not further distribute the material or use it for any profit-making activity or commercial gain

• You may freely distribute the URL identifying the publication in the public portal ?

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

!

!

"#$#%#&'!&(!)*+#,#'-.!/0*1#%234!!

5,#*'2#(#,!67%23-,2%!

(&3!20*!

89 !;-2#&'-.!6/5!)**2#'! -'+!=?&%#2#&'!

C!8D::!

DenverC!/O!

!

!

!

EF7.#,-2#&'!+-2*G!August!8C!2011!

American Chemical Society Division of Medicinal Chemistry 242nd ACS National Meeting, Denver, CO, August 28 - September 1, 2011 J. Barrish, Program Chair

SUNDAY MORNING

General Oral Session J. Barrish, Organizer; D. Hertzog, Presiding Papers 1-10 siRNA S. Barrett, Organizer; M. Cameron, Organizer; M. Cameron, Presiding; S. Barrett, Presiding Papers 11-14

SUNDAY AFTERNOON

General Oral Session J. Barrish, Organizer; K. Seley-Radtke, Presiding Papers 15-25 First Time Disclosure of Clinical Candidate A. J. Robichaud, Organizer; A. J. Robichaud, Presiding Papers 26-30

SUNDAY EVENING

General Poster Session J. Barrish, Organizer Papers 31-157

MONDAY MORNING

Making a Large Impact Through Medicinal Chemistry on Proteins: Methods, Applications to Drug Discovery, and Recent Clinical Results T. Pillow, Organizer; T. Pillow, Presiding Papers 158-163 Innovation in the 21st Century: The Evolution of Drug Discovery D. Beshore, Organizer; D. Beshore, Presiding Papers 164-170

MONDAY AFTERNOON

E. B. Hershberg Award for Important Discoveries in Medicinally Active Substances: Symposium in Honor of Richard B. Silverman J. Barrish, Organizer; J. Zablocki, Presiding Papers 171-175 A Medicinal Chemist's Toolbox: Taking Inventory P. Scola, Organizer; N. Meanwell, Organizer; N. Meanwell, Presiding; P. Scola, Presiding Papers 176-180 Antithrombotic Therapy S. Chackalamannil, Organizer; S. Chackalamannil, Presiding Papers 181-186

MONDAY EVENING

Sci-Mix J. Barrish, Organizer; J. Barrish, Presiding Papers 31, 375, 45, 347, 33, 376, 339, 134, 147, 118, 98, 50, 380, 96, 127, 102, 279, 48, 346, 122, 293, 243, 288, 136, 330, 284, 289, 260, 320, 95, 379, 264, 267, 271, 306, 343, 250, 274

TUESDAY MORNING

General Oral Session J. Barrish, Organizer; J. Barrish, Presiding Papers 187-193 MEDI Awards Symposium J. Zablocki, Organizer; L. Hurley, Organizer; J. Zablocki, Presiding; P. Woster, Presiding Papers 194-201

TUESDAY AFTERNOON

Tissue Selective Therapeutic Agents A. Gilbert, Organizer; B. Raymer, Organizer; P. T. Cheng, Organizer; A. Gilbert, Presiding; B. Raymer, Presiding; P. T. Cheng, Presiding Papers 202-206 GPCR PAMs, NAMs and SAMs: A New Way to Affect GPCR Receptors J. Macor, Organizer; J. Macor, Presiding Papers 207-212

WEDNESDAY MORNING

Drug Discovery Research Centers G. Georg, Organizer; W. Moos, Organizer; G. Georg, Presiding; W. Moos, Presiding Papers 213-217 Targeting Tumor Stem Cells W. Priebe, Organizer; S. Peluso, Organizer; S. Peluso, Presiding; W. Priebe, Presiding Papers 218-222

WEDNESDAY AFTERNOON

Exploiting the Metabolic Differences between Normal and Cancer Cells F. Salituro, Organizer; T. Bannister, Organizer; F. Salituro, Presiding; T. Bannister, Presiding Papers 228-235 Drug Discovery Research Centers G. Georg, Organizer; W. Moos, Organizer; G. Georg, Presiding; W. Moos, Presiding Papers 223-227 Huntington's Disease: Recent Advances in Disease Diagnosis and Potential Disease Modifying Therapeutics C. Dominguez, Organizer; C. Dominguez, Presiding; M. Maillard, Presiding Papers 236WEDNESDAY EVENING General Poster Session J. Barrish, Organizer Papers 242-369

THURSDAY MORNING

General Oral Session J. Barrish, Organizer; J. Barrish, Presiding; P. T. Cheng, Presiding Papers 370-380 From Paper to PK Profile without Synthesis: Everything a Medicinal Chemist Needs to Know About Predictive DMPK J. Kenny, Organizer; J. Kenny, Presiding Papers 381-385 MEDI 1 WITHDRAWN MEDI 2 Discovery of phosphodiesterase-10 (PDE10) inhibitors for the treatment of schizophrenia Izzat T Raheem1, izzat_raheem@merck.com; Jim Barrow2; Rodney A Bednar3; Michael J Breslin1; Joseph Bruno3; Victoria Cofre3; Paul J Coleman1; Christine Fandozzi4; Joy Fuerst5; Lisa Gold6; Nicole Hill5; Pete H Hutson6; Sarah Huszar7; Monika Kandebo6;





Amanda Kemmerer3; Somang H Kim4; Raghu Krishnan3; Wei Lemaire3; Bennett Ma4;

Georgia McGaughey8; Sanjeev Munshi9; Shannon Nguyen7; Sophie ParmentierBatteur6; John D Schreier1; Sujata Sharma9; William D Shipe2; Sean Smith6; Jason Uslaner7; Youwei Yan9; Christopher D Cox1. (1) Program Team Chemistry, Merck & Co., Inc., West Point PA 19486, United States (2) Automated Synthesis and Purification, Merck & Co., Inc., West Point PA 19486, United States (3) In Vitro Sciences, Merck & Co., Inc., West Point PA 19486, United States (4) Drug Metabolism, Merck & Co., Inc., West Point PA 19486, United States (5) Basic Pharmaceutical Sciences, Merck & Co., Inc., West Point PA 19486, United States (6) Neurosymptomatics, Merck & Co., Inc., West Point PA 19486, United States (7) In Vivo Pharmacology, Merck & Co., Inc., West Point PA 19486, United States (8) Chemistry Modeling and Informatics, Merck & Co., Inc., West Point PA 19486, United States (9) Structural Chemistry, Merck & Co., Inc., West Point PA 19486, United States Schizophrenia is a chronic and debilitating neurological disease with onset typically occurring during early adulthood. The disease is characterized by a combination of positive (hallucinations), negative (anhedonia, social withdrawal), and cognitive symptoms, and is estimated to affect 1% of the global population. While currently marketed "typical" and "atypical" therapeutics exist, they are prone to an array of adverse events (AEs), often resulting in discontinuation due to poor efficacy and/or tolerability. As such, alternative pharmacological approaches toward treating schizophrenia represent an unmet medical need. The phosphodiestereases (PDEs) are a superfamily of 11 enzymes responsible for the hydrolytic degradation of the second messengers cAMP and cGMP. Specifically, PDE10 is highly expressed and localized in the mammalian striatum, and is implicated in the regulation of cyclic nucleotide signalling cascades that intersect both the glutamatergic and dopaminergic pathways regulating behavioral control. As such, inhibition of PDE10 is hypothesized to represent a mechanistically novel approach toward the treatment of schizophrenia, and recent preclinical results support this hypothesis. We describe the discovery and development of potent and orally bioavailable tetrahydropyridopyrimidine inhibitors of PDE10 obtained by systematic optimization of a proprietary Merck HTS lead. Leading compounds exhibit sub-nanomolar potencies, excellent pharmacokinetic (PK) properties, and clean off-target profiles. These inhibitors display in vivo target engagement as measured by both an ex vivo occupancy assay and increased striatal cGMP levels upon oral dosing. They also display dose-dependent efficacy in key pharmacodynamic (PD) assays predictive of anti-psychotic activity, including the psychostimulant-induced rat hyperlocomotion assay and the conditioned avoidance response assay.

MEDI 3 Discovery of JNJ-42601572, a γ-secretase modulator with potent, central activity in mouse and dog Francois Bischoff, fbischof@its.jnj.com; Harrie Gijsen, hgijsen@its.jnj.com; Didier Berthelot; Michel De Cleyn; Gregor Macdonald; Daniel Oehlrich; Michel Surkyn; Andres Trabanco; Gary Tresadern; Sven Van Brandt; Adriana I Velter; Herman Borghys;

Chantal Masungi; Marc Mercken. Department of Neuroscience, Janssen Research & Development, Beerse B-2340, Belgium Accumulation of neurotoxic amyloid-beta 42 peptides (Ab42) in the brain is a hallmark of Alzheimer's disease (AD). Gamma-secretase, an intramembrane-cleaving protease responsible for the production of amyloid-beta peptides, has emerged as an important target for the development of novel therapeutics for AD. γ-Secretase modulation rather than plain inhibition has been postulated to be an alternative strategy to intervene pharmacologically within the amyloid cascade. It causes a product shift at the expense of Ab42 to the shorter, more soluble and less amyloidogenic Ab38 without inhibiting NOTCH proteolytic processing. The design and the synthesis of several chemical subclasses of in vitro and in vivo potent γ-secretase modulators (GSM) will be presented as well as their drug-like properties. This study has led to the identification of our lead compound, JNJ-42601572 which, in a non-transgenic mouse brain, upon oral dosing (30 mg/kg, 4 h) induces a 63% lowering of Ab42 levels and a 91% increase of Ab38 levels with unchanged total levels of amyloid peptides. Moreover, JNJ-42601572 elicits very potent in vivo activity across species as it induces upon oral dosing (20 mg/kg, 8 h) a 60% lowering of Ab42 levels and a 60% increase of Ab38 levels in dog cerebrospinal fluid.

MEDI 4 Discovery of a series of brain-penetrant kynurenine aminotransferase II inhibitors for the treatment of schizophrenia Amy B. Dounay, amy.dounay@pfizer.com. Neuroscience Medicinal Chemistry, Pfizer Worldwide Research and Development, Groton CT 06340, United States Kynurenine aminotransferase (KAT) II has been identified as a potential new target for treatment of cognitive impairment associated with schizophrenia. Following a high throughput screen, cyclic hydroxamic acid PF-04859989 emerged as a lead compound for the program. PF-04859989 represents the first reported brain penetrant tool compound for KATII. Additionally, our studies revealed that PF-04859989 inhibits KATII irreversibly by forming a covalent adduct with co-factor pyridoxal phosphate (PLP) in the enzyme active site. Key challenges for the medicinal chemistry team included developing a clear understanding of the structural features affecting the irreversibility of inhibition and design of compounds with potency at both rat and human KATII isozymes. X-ray crystallography, homology modeling, and biophysical studies to probe irreversibility have been critical components of the team's design strategy. Additionally, protein NMR experiments with 13C-labeled PF-04859989 have provided deeper insight into the mechanism of irreversible inhibition. Highlights of these studies and their impact on the team's lead optimization efforts will be described.

MEDI 5 Design and synthesis of Benzimidazole based inhibitors of Raf kinase: A med.

Chem approach towards the discovery of Phase II clinical candidate RAF265 Savithri Ramurthy1, savithri.ramurthy@novartis.com; Payman Amiri2; Abran Costales1;

Johanna M Jansen1; Barry Levine3; Sylvia Ma2; Christopher M McBride3; Teresa Pick4;

Daniel J. Poon1; Cynthia M. Shafer1; Darrin Stuart2; Leonard Sung3; Ahmad Hashash5;

Paul Renhowe1; Eleni Venetsanakos2; Jeremy Murray3; Brent Appleton1; Mina Aikawa2;

Joelle Verhagen3; Kimberly Aarderlin2. (1) Global Discovery chemistry / Oncology and Exploratory Chemistry, Novartis Institutes for Biomedical Research, Emeryville CA 94608, United States (2) Oncolgy, Novartis Institutes for Biomedical Research, Emeryville CA 94608, United States (3) NA, United States (4) Lawrence Livermore Laboratories, United States (5) Gilead Sciences, United States The Ras/Raf/MEK/ERK pathway plays a central role in mediating proliferation and survival signals from the cell membrane to the nucleus and cytoplasm. Activation of this pathway often occurs in cancer cells, the importance of which is underscored by the observation that activating mutations in Ras and B-Raf frequently occur in human cancer. Thus a potent Raf inhibitor could have a significant impact in treating cancers that are dependent on activated Ras or Raf for survival and proliferation signaling.

Malignant melanoma represents a promising indication for a Raf inhibitor given the high percentage of B-Raf (60-70%) mutations and the huge unmet medical need. Here, we describe the medicinal chemistry approaches which led to the discovery of Raf265, a novel, orally bioavailable small molecule inhibitor of c-Raf, B-Raf and mutant B-Raf (V600E) that also inhibits VEGFR-2. This target profile provides two potential mechanisms for inhibiting tumor growth: direct anti-proliferative/pro-apoptotic effects on tumor cells through inhibition of Raf, and anti-angiogenic activity through inhibition of VEGFR-2. Design strategy, synthesis and the in vitro, in vivo activities of the early Benzimidazole analogs and Raf 265 will also be discussed.

MEDI 6



Pages:   || 2 | 3 | 4 | 5 |   ...   | 38 |


Similar works:

«2012 WIND TECHNOLOGIES MARKET REPORT AUGUST 2013 This report is being disseminated by the U.S. Department of Energy (DOE). As such, this document was prepared in compliance with Section 515 of the Treasury and General Government Appropriations Act for fiscal year 2001 (public law 106-554) and information quality guidelines issued by DOE. Though this report does not constitute “influential” information, as that term is defined in DOE’s information quality guidelines or the Office of...»

«Program in Law and PubLic affairs Annual Report 2007–08 1 http://lapa.princeton.edu 2 Annual Report of The Program in Law and Public Affairs TABLE OF CONTENTS LAPA EVENTS 27 DIRECTOR’S INTRODUCTION 5 LAPA Seminars LAPA AND LAW AT PRINCETON UNIVERSITY 7 Public Lectures, Conferences and Panels THE PEOPLE AT LAPA 10 Invitational Academic Symposia THE LAPA FELLOWS PROGRAM 14 Co-Sponosored Events 2007-08 Fellows LAPA STUDENT PROGRAMS 40 Distinguished Guests and Visiting Scholars: Fellow...»

«Faculty of Law States rights and obligations in case of illegal drug trafficking by the sea — CANDIDATE NO.4 Master thesis in Law of the Sea. August 2014 Table of Content 1. Introduction 1.1 Introduction 1.2 Sources and methods of the thesis 1.3Structure of the work 2. Illegal drug trafficking by the sea as crime that has international character 2.1 Introduction 2.2 Types of the crimes in international law 2.3 Illegal drug trafficking by the sea and its elements 3. Flag State rights and...»

«KONRAD ADENAUER STIFTUNG AFRICAN LAW STUDY LIBRARY Volume 12 Edited by Hartmut Hamann, Ibrahima Diallo and Chadidscha Schoepffer Hartmut Hamann is a lawyer specialized in providing legal support for international projects between states and private companies, and in international arbitration proceedings. He is a professor at the Freie Universität Berlin, and at the Chemnitz University of Technology, where he teaches public international law and conflict resolution. His legal and academic...»

«145 Claiming Rights: Organizational and Discursive Strategies of the Korean Adoptee and Unwed Mothers Movement* Paul Y. Chang** Andrea Kim Cavicchi*** Since the Korean War, the South Korean adoption industry has grown to be one of the largest in the world today. In 2011, the National Assembly of the Republic of Korea changed the name of the Special Law Relating to the Promotion and Process of Adoption *** This work was supported by the National Research Foundation of Korea Grant funded by the...»

«Computer Science & Information Technology 47 David C. Wyld Natarajan Meghanathan (Eds) Computer Science & Information Technology Seventh International Conference on Networks & Communications (NETCOM 2015) Sydney, Australia, December 26~27, 2015 AIRCC Publishing Corporation Volume Editors David C. Wyld, Southeastern Louisiana University, USA E-mail: David.Wyld@selu.edu Natarajan Meghanathan, Jackson State University, USA E-mail: nmeghanathan@jsums.edu ISSN: 2231 5403 ISBN: 978-1-921987-44-1 DOI...»

«2005 Annual Retail Chain Survey Partial List of Retail Chain Stores 010 New Car Dealers 441110 New Car Dealers LEGAL NAME COMPLEXE DE L'AUTO PARK AVENUE INC. DON VALLEY NORTH AUTOMATIVE INC. HICKMAN MOTORS LIMITED JIM PATTISON INDUSTRIES LTD JOHN SCOTTI AUTOMOTIVE LIMITEE LOUNSBURY COMPANY LIMITED MERCEDES-BENZ CANADA INC OPENROAD AUTO GROUP LIMITED THE DICK IRWIN GROUP LTD THE ROYAL GARAGE LIMITED 020 Used and Recreational Motor Vehicle and Parts Dealers 441120 Used Car Dealers LEGAL NAME...»

«Tokomane ya Therišano 139 TSHEKASEKO YA MOLAO WA KGATELELO YA BOLOI (MOLAO 3 WA 1957) Projeke 135 Letšatšikgwedi la mafelelo bakeng sa diswayaswayo: 30 Moranang 2016 ISBN: 978-0-621-44208-3 ii MATSENO Khomišene ya Kaonafatšo ya Molao ya Afrika Borwa e hlanngwe ka South African Law Reform Commission Act, 1973 (Molao 19 wa 1973). Maloko a khomišene keMoahlodi Mandisa Muriel Lindelwa Maya (Modulasetulo) Moahlodi NaranNgaka an (Jody) Kollapen (Motlatša Modulasetulo) Moprofesa Marita...»

«amnesty international USA: Trials in error Third go at misconceived military commission experiment Military commissions wrong choice in 2001, wrong in 2006, and would be wrong now 16 July 2009 AI Index: AMR 51/083/2009 There is still much to do before the Guantánamo chapter is truly brought to a close. Its remaining inmates must either be tried before a court of law – like any other suspected criminal – or set free Statement by the UN High Commissioner for Human Rights, Navanethem Pillay,...»

«ON THE JOB I. Getting Acquainted Carl Lawrence was somewhat nervous on his first day at work. Although a very good student, he had relatively little practical experience in engineering. Yet, here he was, supervisor of several acid and caustic distribution systems. Plant manager, Kevin Rourke, gave Carl a tour of the facilities and introduced him to the workers he would be supervising. Carl was pleasantly surprised when he was introduced to Rick Duffy. Rick and Carl's older brother were best...»

«UNITED STATES DISTRICT COURT DISTRICT OF DELAWARE IN RE MOLSON COORS BREWING ) CIVIL ACTION NO. 05-294-KAJ COMPANY SECURITIES LITIGATION ) CONSOLIDATE D CONSOLIDATED AMENDE D CLASS ACTION COMPLAINT FOR VIOLATION O F THE FEDERAL SECURITIES LAW S Plaintiffs, by their counsel, make the following allegations upon information and belief based upon all of the facts set forth below, which were obtained through an extensive investigation made by and through their attorneys. Lead Counsel's...»

«19 6 ВЛАСТЬ 2 015 ’ 0 7 Список литературы Государственная тайна и ее защита в Российской Федерации: учебно-практическое пособие (под ред. М.А. Вуса и А.В. Федорова). 2007. СПб.: Юридический центр Пресс. 752 с. Макаров О.С. 2014. Правовое обеспечение информационной безопасности на примере...»





 
<<  HOME   |    CONTACTS
2016 www.dissertation.xlibx.info - Dissertations, online materials

Materials of this site are available for review, all rights belong to their respective owners.
If you do not agree with the fact that your material is placed on this site, please, email us, we will within 1-2 business days delete him.